CSCO 2026 | Professor Aijun Liu: Phase II Study of Eprenetapopt Combined With Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma
The 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) was held in Jinan from September 16 to 19, 2026, bringing together oncology experts from around the world to explore innovative approaches to precision diagnosis and treatment. During the multiple myeloma session, Professor Aijun Liu of Beijing Chao-Yang Hospital, Capital Medical University, presented an update on a phase II clinical study of eprenetapopt combined with bispecific antibodies in relapsed/refractory multiple myeloma (RRMM). In an interview with Oncology Frontier – Hematology Frontier, Professor Liu discussed the rationale behind the study design, the underlying mechanisms, the efficacy and safety profile of the combination, and directions for future research. The interview is presented below.









